Alan David Kaye1, Elyse M Cornett2, Brendon Hart3, Shilpadevi Patil3, Andrew Pham4, Matthew Spalitta5, Kenneth F Mancuso1. 1. Department of Anesthesiology, LSU School of Medicine, LSUHSC, 1542 Tulane Ave, New Orleans, LA, 70112, USA. 2. Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. ecorne@lsuhsc.edu. 3. Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. 4. Tulane University School of Medicine, New Orleans, LA, USA. 5. LSU New Orleans School of Medicine, New Orleans, LA, USA.
Abstract
PURPOSE OF REVIEW: Opioid use and abuse has led to a worldwide opioid epidemic. And while opioids are clinically useful when appropriately indicated, they are associated with a wide range of dangerous side effects and whether they are effective at treating or eliminating chronic pain is controversial. There has long been a need for the development of nonopioid alternative treatments for patients that live in pain, and until recently, only a few effective treatments were available. Today, there are a wide range of nonopioid treatments available including NSAIDs, acetaminophen, corticosteroids, nerve blocks, SSRIs, neurostimulators, and anticonvulsants. However, these treatments are still not entirely effective at treating pain, which has sparked a new exploration of novel nonopioid pharmacotherapies. RECENT FINDINGS: This manuscript will outline the most recent trends in novel nonopioid pharmacotherapy development including tramadol/dexketoprofen, TrkA inhibitors, tapentadol, opioid agonists, Nektar 181, TRV 130, ßarrestin2, bisphosphonates, antibodies, sodium channel blockers, NMDA antagonists, TRP receptors, transdermal vitamin D, AAK1 kinase inhibition, calcitonin gene-related peptide (CGRP), TRPV4 antagonists, cholecystokinin, delta opioid receptor, neurokinin, and gene therapy. The pharmacotherapies discussed in this manuscript outline promising opioid alternatives which can change the future of chronic pain treatment.
PURPOSE OF REVIEW: Opioid use and abuse has led to a worldwide opioid epidemic. And while opioids are clinically useful when appropriately indicated, they are associated with a wide range of dangerous side effects and whether they are effective at treating or eliminating chronic pain is controversial. There has long been a need for the development of nonopioid alternative treatments for patients that live in pain, and until recently, only a few effective treatments were available. Today, there are a wide range of nonopioid treatments available including NSAIDs, acetaminophen, corticosteroids, nerve blocks, SSRIs, neurostimulators, and anticonvulsants. However, these treatments are still not entirely effective at treating pain, which has sparked a new exploration of novel nonopioid pharmacotherapies. RECENT FINDINGS: This manuscript will outline the most recent trends in novel nonopioid pharmacotherapy development including tramadol/dexketoprofen, TrkA inhibitors, tapentadol, opioid agonists, Nektar 181, TRV 130, ßarrestin2, bisphosphonates, antibodies, sodium channel blockers, NMDA antagonists, TRP receptors, transdermal vitamin D, AAK1 kinase inhibition, calcitonin gene-related peptide (CGRP), TRPV4 antagonists, cholecystokinin, delta opioid receptor, neurokinin, and gene therapy. The pharmacotherapies discussed in this manuscript outline promising opioid alternatives which can change the future of chronic pain treatment.
Authors: David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe Journal: Ann Neurol Date: 2011-07-27 Impact factor: 10.422
Authors: Henry I Mosberg; Larisa Yeomans; Jessica P Anand; Vanessa Porter; Katarzyna Sobczyk-Kojiro; John R Traynor; Emily M Jutkiewicz Journal: J Med Chem Date: 2014-03-26 Impact factor: 7.446
Authors: Timothy F Platts-Mills; Samuel A McLean; Morris Weinberger; Sally C Stearns; Montika Bush; Brittni B Teresi; Karen Hurka-Richardson; Kurt Kroenke; Robert D Kerns; Mark A Weaver; Francis J Keefe Journal: Trials Date: 2020-07-06 Impact factor: 2.279
Authors: Andrew J Poole; Laura Frigotto; Matthew E Smith; Claudia Baar; Gabriela Ivanova-Berndt; Agnes Jaulent; Catherine Stace; Christopher G Ullman; Anna V Hine Journal: Sci Rep Date: 2019-01-30 Impact factor: 4.379